Entera Bio (ENTX) Return on Capital Employed (2022 - 2026)
Entera Bio's (ENTX) quarterly Return on Capital Employed came in at 96.79% in Q1 2026, down 2383.0% YoY from 4.24% in Q1 2025, and down 21.04% on a QoQ basis from 79.96% in Q4 2025.
Entera Bio (ENTX) Return on Capital Employed (2022 - 2026) Analysis & Trends
Entera Bio (ENTX) has 5 years of Return on Capital Employed data on file, last reported at 96.79% in Q1 2026.
- Quarterly Return on Capital Employed fell 2383.0% year-over-year to 96.79% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 96.79% (down 2383.0% YoY) and the FY2025 annual result came in at 109.92%, down 797.0% from the prior year.
- Return on Capital Employed retreated to 96.79% in Q1 2026, from 79.96% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 56.53% in Q2 2025 to a low of 133.67% in Q3 2023.
- A 5-year average of 93.06% and a median of 96.79% in 2026 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed sank 4660 bps — and 2025, when it jumped 5464 bps.
- Tracing ENTX's Return on Capital Employed over 5 years: stood at 100.19% in 2022, then increased by 2 bps to 97.98% in 2023, then sank by 33 bps to 130.18% in 2024, then jumped by 39 bps to 79.96% in 2025, then decreased by 21 bps to 96.79% in 2026.
- The last three Return on Capital Employed figures came in at 96.79% (Q1 2026), 79.96% (Q4 2025), and 64.25% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Entera Bio | 158.42 Mn | 147.11 Mn | - | -101.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -101.62% |
| Mar 31, 2026 | -96.79% |
| Dec 31, 2025 | -79.96% |
| Sep 30, 2025 | -64.25% |
| Jun 30, 2025 | -56.53% |
| Mar 31, 2025 | -72.96% |
| Dec 31, 2024 | -130.18% |
| Sep 30, 2024 | -118.89% |
| Jun 30, 2024 | -97.38% |
| Mar 31, 2024 | -88.46% |
| Dec 31, 2023 | -97.98% |
| Sep 30, 2023 | -133.67% |
| Jun 30, 2023 | -114.35% |
| Mar 31, 2023 | -104.80% |
| Dec 31, 2022 | -100.19% |
| Sep 30, 2022 | -87.07% |
| Jun 30, 2022 | -75.72% |
| Mar 31, 2022 | -62.86% |